TheraRadar
← Back
Data updated: Jun 28, 2026

THEA PHARMA

Specialty
CardiovascularOphthalmologyInfectious Disease Execution: Good

THEA PHARMA is a specialty pharmaceutical company focused on Cardiovascular, Ophthalmology, Infectious Disease. Key products include COSOPT PF.

1995
Since
9
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
7 Small Molecules

THEA PHARMA at a Glance

  • Fast trial execution (15 months median completion)

THEA PHARMA's Key Drugs

THEA PHARMA's core commercial portfolio centers on COSOPT PF, ZOLYMBUS, IYUZEH, spanning Cardiovascular and Ophthalmology — its most strategically important drugs approved in the last 15 years.

COSOPT PF
Ophthalmology

Glaucoma

Beta-1 adrenergic receptor Approved 2012
ZOLYMBUS
Ophthalmology

Open-Angle Glaucoma

Approved 2025
IYUZEH
Ophthalmology

Glaucoma

Approved 2022
ZIOPTAN
Ophthalmology
FP prostanoid receptor Approved 2012

THEA PHARMA's Recent FDA Approvals

THEA PHARMA secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

ZOLYMBUS NDA
2025-09-09
bimatoprost
Open-Angle Glaucoma
CYKLX NDA
2025-08-15
articaine hydrochloride
1 INDICATIONS AND USAGE Articaine HCl and Epinephrine is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age and older. Articaine HCl and Epinephrine is a combination of articaine HCl, an amide local anesthetic, and epinephrine, a vasoconstrictor, indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age and older ( 1 ).

THEA PHARMA's Therapeutic Areas

THEA PHARMA's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Ophthalmology, across 0 biologic and 7 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 44%
4 drugs
Ophthalmology 44%
4 drugs
Infectious Disease 11%
1 drugs

THEA PHARMA's Top Competitors

THEA PHARMA's closest competitors by therapeutic-area and drug-target overlap include B BRAUN, BAUSCH AND LOMB INC, and FOUGERA PHARMS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

B BRAUN specialty
Infectious Disease, Ophthalmology, Cardiovascular
BAUSCH AND LOMB INC other
Ophthalmology, Cardiovascular, Infectious Disease
FOUGERA PHARMS other
Ophthalmology, Cardiovascular, Infectious Disease
Novartis big-pharma
Cardiovascular, Ophthalmology
Merck big-pharma
Infectious Disease, Cardiovascular

THEA PHARMA Pipeline Snapshot

Active clinical trials for THEA PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • COSOPT PF leads revenue
  • • 4 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 10/11 completed
  • • Speed: 15 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges